Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Portal: Long-Term Safety and Tolerability of PDS With Ranibizumab in nAMD
NCT03683251Phase 3Recruiting
- Sponsor
- Roche
- Start
- Sep 2018
- Primary completion
- Dec 2029
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Sep 2018; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03683251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03683251.